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Abstract: Hypertension is a growing global health problem, and is predicted to affect 1.56 billion 
people by 2025. Treatment remains suboptimal, with control of blood pressure achieved in 
only 20%–35% of patients, and the majority requiring two or more antihypertensive drugs to 
achieve recommended blood pressure goals. To improve blood pressure control, the European 
hypertension guidelines recommend that angiotensin II receptor blockers (ARBs) or angiotensin-
converting enzyme inhibitors (ACEIs) are combined with calcium channel blockers (CCBs) 
and/or thiazide diuretics. The rationale for this strategy is based, in part, on their different effects 
on the renin-angiotensin system, which improves antihypertensive efficacy. Data from a large 
number of trials support the efficacy of ACEIs or ARBs in combination with CCBs and/or 
hydrochlorothiazide (HCTZ). Combining two different classes of antihypertensive drugs has 
an additive effect on lowering of blood pressure, and does not increase adverse events, with the 
ARBs showing a tolerability advantage over the ACEIs. Among the different ARBs, olmesartan 
medoxomil is available as a dual fixed-dose combination with either amlodipine or HCTZ, and 
the increased blood pressure-lowering efficacy of these two combinations is proven. Triple 
therapy is required in 15%–20% of treated uncontrolled hypertensive patients, with a renin-
angiotensin system blocker, CCB, and thiazide diuretic considered to be a rational combination 
according to the European guidelines. Olmesartan, amlodipine, and HCTZ are available as a 
triple fixed-dose combination, and significant blood pressure reductions have been observed with 
this regimen compared with the possible dual combinations. The availability of these fixed-dose 
combinations should lead to improvement in blood pressure control and aid compliance with 
long-term therapy, optimizing the management of this chronic condition.
Keywords: angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium 
channel blockers, triple therapy, hypertension
Introduction
Globally, hypertension is the most common preventable cause of death, accounting for 
7.5 million deaths in 2004,1 yet it remains an increasing health problem.2 At the start 
of the 21st century, over a quarter of the world’s adult population had   hypertension 
(972 million), and this is predicted to increase by about 60% to 1.56 billion in 2025.3 
The relationship between increasing blood pressure and cardiovascular risk is well 
established,4 with even modest changes in blood pressure substantially increasing 
cardiovascular risk.5
Recent hypertension guidelines, produced by the European Society of 
Hypertension and the European Society of Cardiology, state that the primary goal of 
treatment is to achieve the maximum reduction in long-term total risk of c  ardiovascular 
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  morbidity and mortality.6 A reduction in systolic blood 
pressure/  diastolic blood pressure to ,140/90 mmHg is 
r  ecommended in all patients with hypertension. More 
recently, the 2009 reappraisal of the European Society of 
Hypertension guidelines recommends that reducing blood 
pressure to within the range of 130−139/80−85 mmHg in 
all hypertensive patients may be prudent.6,7
Despite the widely recognized relationship between 
high blood pressure and cardiovascular risk, and clear 
h  ypertension guidelines, overall blood pressure control 
rates remain suboptimal and a growing public health 
c  oncern worldwide. According to the findings of a sys-
tematic l  iterature review conducted in established market 
economies, on average 20%–35% of treated hypertensive 
patients had their blood pressure controlled.8,9 A significant 
example of poor blood pressure control is seen in epide-
miological data from over 52,000 hypertensive patients in 
Italy, who also had a high prevalence of concomitant risk 
factors, including hypercholesterolemia (55.9%), obesity 
(36.4%), smoking (28.7%), and diabetes (15.0%),10 putting 
about 50% of the overall hypertensive population at high or 
very high risk of cardiovascular morbidity and mortality. 
This is particularly relevant because overall blood pres-
sure control has been shown to be worse in patients with 
increasing numbers of risk factors, as demonstrated in a 
review of data from over 22,000 hypertensive patients in 
26 countries.9 This is also of concern, because one would 
expect this higher-risk population to be receiving more 
intensive blood pressure control. In addition, suboptimal 
blood pressure control is also causing a growing eco-
nomic burden, accounting for direct health care costs of 
US$372 billion in 2001, which are predicted to increase 
to US$908 billion in 2011.11 One factor that may well be 
c  ontributing to the suboptimal rates of blood   pressure 
control is the prevailing use of monotherapy in clinical 
practice. Blood pressure targets are achieved in only a 
limited number of patients using monotherapy, while the 
majority require two or more antihypertensive agents.6,7 
The European guidelines recommend the use of a combina-
tion of two drugs at low doses, even as an initial treatment 
when hypertensive patients have marked blood pressure 
elevation or high blood pressure elevation in association 
with s  ubclinical organ damage, di  abetes, renal disease, 
or cardiovascular disease.6 This approach is also recom-
mended by the Joint National C  ommittee on Prevention, 
Detection, Evaluation, and T  reatment of High Blood 
  Pressure.12 Furthermore, even though combining two drugs 
may significantly improve   efficacy, it is estimated that for 
a relevant   proportion of patients, this may not be enough, 
thus 15%−20% of patients require combination therapy 
with three agents to control blood pressure effectively.7
This review will look at the rationale for using 
  combination therapy to optimize blood pressure control, 
provide a summary of the evidence to support the preferred 
combinations, and focus on the use of angiotensin II receptor 
blocker (ARB)-based dual or triple combinations as examples 
of effective and well tolerated treatments, mostly those based 
on olmesartan medoxomil.
Blood pressure control: rationale  
for combination therapy
The most commonly used antihypertensive drugs are the 
renin-angiotensin system blockers, ie, angiotensin-converting 
enzyme inhibitors (ACEIs),  ARBs, calcium channel block-
ers (CCBs), beta-blockers, and thiazides, and combining 
these classes has a number of beneficial effects. Firstly, 
combination therapy, which uses drugs with different and 
complementary mechanisms of action, can provide syn-
ergistic effects on blood pressure, thus providing higher 
antihypertensive efficacy than the individual components. 
The blood pressure-lowering effect of combination therapy 
can be predicted on the basis of the additive effects of 
the individual components, according to the findings of a 
meta-analysis of 42 randomized, factorial clinical trials, 
performed in approximately 11,000 patients with arte-
rial hypertension.13 According to this analysis, the blood 
pressure-lowering efficacy of combining two different 
classes is approximately five times greater than doubling 
the dose of one of the components. Secondly, the blood 
pressure-lowering efficacy of the different antihyperten-
sive drug classes is, as expected, also accompanied by 
reductions in the risk of developing coronary heart dis-
ease and stroke.14 Thirdly, a reduction in adverse events 
is frequently observed with specific combination strate-
gies; adverse events are less than   additive.15 In addition, 
combination therapy has been associated with a lower 
rate of discontinuation, compared with initiating treat-
ment with monotherapy, having the lowest rates associ-
ated with the use of renin-angiotensin system blockers.16 
Finally, combination therapy may allow dose titration of 
treatment without increasing pill burden, an important 
factor in the treatment of a condition in which compli-
ance has important benefits for patient health,17 and that 
is frequently associated with other clinical conditions, 
which require other drugs (antidiabetic, lipid-lowering, 
antiplatelet agents).
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Possible combination therapies
It is possible to understand why combination therapy is so 
effective by considering the effects of the major classes of 
antihypertensive agents on the renin-angiotensin system, 
which is a key biological system, playing a major role in the 
regulation of blood pressure and in the pathophysiology of 
hypertension. Secretion of renin is regulated by arterial pres-
sure, negative feedback by angiotensin II, sodium chloride 
delivery to the macula densa, and activity of the sympathetic 
nervous system.18 Each class of antihypertensive treatment 
has a different effect on the renin-angiotensin system, ie, 
CCBs and diuretics stimulate the renin-angiotensin system 
to compensate for the reduced pressure in the glomerular 
afferent arteriolar and loss of sodium, respectively, whilst the 
ARBs, ACEIs, beta-blockers, and the direct renin inhibitor, 
aliskiren, inhibit the renin-angiotensin system at different 
levels, interfering with different mechanisms (Figure 1).
Large-scale studies involving ARBs have demonstrated 
the efficacy of these agents in reducing cardiovascular and 
cerebrovascular risk in important groups of hypertensive 
patients. SCOPE (The Study on Cognition and Prognosis in 
the Elderly) showed that in elderly patients (aged 70–89 years), 
blood pressure-lowering with an ARB reduced major cardio-
vascular events as effectively as treatment with placebo (plus 
additional antihypertensive agents except ACEIs or ARBs).19 
Studies in high-risk patients, including those with cardiovas-
cular disease, atrial fibrillation, recent stroke, and impaired 
glucose tolerance, have also shown ARB treatment to be as 
effective as placebo in reducing the risk of   cardiovascular 
outcomes.20–23 Moreover, data from the SCOPE, LIFE, 
(Losartan Intervention For Endpoint reduction), and the 
MOSES (MOrbidity and mortality after Stroke,   Eprosartan 
compared with nitrendipine for   Secondary p  revention) studies 
provide encouraging   indications that ARBs may be beneficial 
in reducing the risk of stroke.19,24,25
On the basis of their opposite effects on the renin-angiotensin 
system, effective antihypertensive treatment   combinations are 
those based on the association of renin-angiotensin system 
blockers with CCBs or diuretics, which have stronger antihy-
pertensive efficacy when used in combination.
In terms of the preferred combinations, outcomes data 
from large, randomized studies, including LIFE, ASCOT-
BPLA (Anglo-Scandinavian Cardiac Outcomes Trial-Blood 
Pressure Lowering Arm) and INVEST (the International 
Verapamil-Trandolapril Study) trials, suggest that renin-
angiotensin system-based combinations may be superior to 
beta-blocker plus thiazide combinations in terms of cardio-
vascular morbidity and mortality.25–27 Furthermore, the use 
of a beta-blocker in combination with a diuretic is currently 
not recommended in predisposed patients due to the more 
likely development of diabetes,7,28 while the outcome of 
using a beta-blocker in combination with a CCB has not been 
properly investigated.7
Thus, the preferred combinations of antihypertensive 
drugs according to the European Society of Hypertension/
European Society of Cardiology guidelines include ARBs 
and CCBs, ACEIs or CCBs, ARBs and thiazide diuretics, 
or ACEIs and thiazide diuretics.6,7 The association of direct 
renin inhibitors and thiazide diuretics or CCBs is currently 
under investigation.
Angiotensin 1
Na+ excretion
Vasoconstriction
Calcium channel blocker
Diuretic
Angiotensin 1
Renin
ACE ACE inhibitor
Angiotensin II
Angiotensin receptor
blocker
AT1 receptor
Direct renin inhibitor
Beta-blockers
Figure 1 Effects of antihypertensive drugs that inhibit the renin-angiotensin system.18
Copyright © 2007. Reprinted with permission from BMJ Publishing Group Ltd. Brown MJ. Renin: friend or foe? Heart. 2007;93(9):1026–1033.
Abbreviations: ACE, angiotensin-converting enzyme; AT1, angiotensin type 1.
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Efficacy
Combining two different classes of antihypertensive drugs 
has been shown to provide an additive blood pressure-
  lowering effect,15 and data from a large number of trials 
shows the efficacy of using ACEIs or ARBs in combination 
with CCBs or diuretics to improve blood pressure control.7
The blood pressure-lowering efficacy of an ACEI (per-
indopril) plus diuretic (indapamide) combination was more 
than twice that of single-drug therapy in the PROGRESS 
(perindopril protection against recurrent stroke) trial.29 
Similarly the antihypertensive efficacy of such a combination 
was confirmed in the ADVANCE (Actions in Diabetes and 
Vascular A reduction in disease: preterAx and diamicroN-MR 
Controlled Evaluation) trial and in the HYVET (HYperten-
sion in the Very Elderly Trial).30,31
Amlodipine plus perindopril was more effective in low-
ering blood pressure and preventing major cardiovascular 
events compared with a beta-blocker and diuretic in the 
ASCOT-BPLA trial.26 In INVEST, 2-year blood pressure 
control was similar in those patients receiving verapamil 
plus trandolapril compared with the combination of a beta-
blocker and diuretic.27 A similar reduction in blood pressure 
was also observed with amlodipine plus benazepril compared 
with benazepril plus hydrochlorothiazide (HCTZ) in the 
ACCOMPLISH (Avoiding Cardiovascular Events through 
Combination Therapy in Patients Living with Systolic 
Hypertension) trial, whilst the ACEI plus CCB combina-
tion was more effective in reducing the primary combined 
cardiovascular outcome of that study.32
For a similar reduction in blood pressure, losartan-based 
therapy (initial combination with HCTZ) reduced cardio-
vascular morbidity and mortality to a greater extent than 
atenolol-based therapy in the LIFE trial.25 In the VALUE 
(Valsartan Antihypertensive Long-term Use Evaluation) 
trial, there was no difference in cardiovascular morbidity 
and mortality between valsartan plus HCTZ compared with 
amlodipine plus HCTZ.33 The reduction in blood pressure was 
substantially similar in both groups, although amlodipine-
based therapy had a more pronounced blood pressure-
lowering effect in the first months of therapy.
Tolerability
Unlike the additive blood pressure-lowering effects observed 
with combining two different classes of antihypertensive 
drugs, adverse effects are less than additive.15 Moreover, the 
complementary mechanisms of action of the different classes 
of antihypertensive treatments may even lead to a reduction 
of some adverse events in specific cases. For example, 
peripheral edema is a common adverse effect of CCBs, 
which is reduced when a CCB is administered in combination 
with an ARB or ACEI.34 A recent example of this favorable 
effect using ARBs is provided by the COACH (Combina-
tion of Olmesartan Medoxomil and Amlodipine Besylate in 
Controlling High Blood Pressure) study, described later in 
this review.35
Whilst the combinations of antihypertensive agents are 
generally well tolerated and consistent with the component 
agents, there are important differences in the adverse event 
profiles of the different classes. Adverse events with CCBs 
and thiazides are strongly dose-related, whilst those observed 
with ACEIs and ARBS are much less related to dose. On 
this basis, ACEIs and ARBs can be used at full doses in 
combination regimens.15 Even though ACEIs and ARBs are 
well tolerated, clinical studies like ONTARGET (Ongo-
ing Telmisartan Alone and in Combination with Ramipril 
Global End-point Trial) show that ARBs have a significant 
tolerability advantage over ACEIs.36 In this large study, the 
frequency of cough and angioedema leading to permanent 
discontinuation was more common in the ramipril group than 
in the telmisartan group (Table 1).
It should be mentioned here that, in 2011, two clinical 
trials reported safety issues relating to the use of olmesartan 
in high-risk patients. Each of these studies involved patients 
with type 2 diabetes who were randomized to treatment 
with olmesartan or placebo plus additional antihypertensive 
agents (except ACEIs or ARBs) as needed for blood pres-
sure control. The ROADMAP (Randomized Olmesartan 
and Diabetes MicroAlbuminuria Prevention) trial involved 
mainly Caucasian patients with diabetes and at least one other 
cardiovascular risk factor, who were at risk of developing 
microalbuminuria. In ROADMAP, 15 (0.7%) deaths due 
to cardiovascular causes occurred in the olmesartan group 
and 3 (0.1%) in the placebo group (P = 0.01). The authors 
  suggested that this difference may simply have been a chance 
outcome caused by the low numbers of these events.37   
Table 1 Tolerability profiles of ramipril and telmisartan leading 
to permanent discontinuation in the ONTARGET study36
Reason for permanent  
discontinuation
Patients (n, %)
Ramipril  
(n = 8576)
Telmisartan   
(n = 8542)
Cough 360 (4.2) 93 (1.1)
Hypotensive symptoms 149 (1.7) 229 (2.7)
Renal impairment 60 (0.7) 68 (0.8)
Angioedema 25 (0.3) 10 (0.1)
Syncope 15 (0.2) 19 (0.2)
Diarrhea 12 (0.1) 19 (0.2)
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  The ORIENT (Olmesartan Reducing Incidence of Endstage 
renal disease in diabetic Nephropathy Trial) involved Eastern 
Asian patients with diabetes and overt nephropathy. There 
were 10 cardiovascular deaths (3.5%) in the olmesartan 
group and three (1.1%) in the placebo group, and the authors 
suggested that the higher number of deaths in the olmesar-
tan group may have been related to the higher number of 
patients with a history of cardiovascular problems in the 
former group.38
More recently, the impact of the OLIVUS (OLmesartan 
on progression of coronary atherosclerosis: evaluation by 
intraVascular UltraSound) study looked at Japanese patients 
with stable angina pectoris and established coronary artery 
disease who were randomized to treatment with olmesartan 
or placebo plus additional antihypertensive agents (except 
ACEIs or ARBs). This study found no difference in the rate 
of cardiovascular or cerebrovascular events between the two 
groups, although a composite event rate of cardiovascular 
and cerebrovascular deaths, myocardial infarction, stroke, 
angina, and heart or renal failure was significantly lower 
in the olmesartan group (P = 0.041).39 Further insights 
into the safety of olmesartan may come from the OSCAR 
(OlmeSartan and Calcium Antagonists Randomized) study 
which is comparing the effects of olmesartan monotherapy 
with an olmesartan plus CCB combination on cardiovascular 
morbidity and mortality in elderly Japanese hypertensive 
patients at increased cardiovascular risk.40 Perhaps the final 
point in this regard is that the United States Food and Drug 
Administration carried out an investigation into the safety 
data from the ROADMAP and ORIENT studies, found no 
safety concerns, and concluded that the benefits of olmesartan 
continue to outweigh its potential risks for the treatment of 
high blood pressure.41
ARB-based combination therapy
Recent European guidelines highlighted the need to over-
come the persistent prevailing use of monotherapy in the 
treatment of hypertension and recommend the use of combi-
nation therapy in the majority of patients. In this regard, the 
2009 reappraisal of the guidelines highlights the benefits of 
renin-angiotensin system-based combinations.6,7
The efficacy of ARBs is based on their ability to antago-
nize selectively the binding of angiotensin II to the angio-
tensin II type 1 (AT1) receptor; the differences reported 
between class members are mostly explained by differences 
in dosing.42 For example, olmesartan 20 mg and irbesartan 
300 mg have been shown to block the blood pressure response 
to exogenous angiotensin II completely, whilst the effect was 
blocked to a lesser extent with valsartan 160 mg and losartan 
100 mg.43 Such differences in the ability to block the AT1 
receptor appear to translate into differences in duration of 
antihypertensive efficacy. An independent meta-analysis 
of studies that used ambulatory blood pressure monitoring 
showed that the magnitude of blood pressure reductions 
depended upon the agent used.44 This is in line with the 
results of direct head-to-head clinical comparisons, which 
have shown that some members of the ARB class, particularly 
olmesartan medoxomil, provide highly effective blood pres-
sure reductions over 24 hours.45–47 This observation suggests 
that dual or triple fixed-combination therapies based upon 
olmesartan can provide effective and sustained control of 
blood pressure levels. The increased blood pressure-lowering 
efficacy of a dual fixed-dose combination of olmesartan with 
either amlodipine or HCTZ has been confirmed in a number 
of clinical studies.35,48–52
The COACH study provides a good example of the 
beneficial effects of combination therapy. In this 8-week, 
randomized, double-blind, factorial study, the antihyper-
tensive efficacy of olmesartan (10 mg, 20 mg, or 40 mg) 
in combination with amlodipine (5 mg, 10 mg) was com-
pared with component monotherapies in 1940 patients 
with mild-to-severe hypertension.35 Significantly greater 
dose-dependent reductions in seated diastolic blood pressure 
and systolic blood pressure were observed with olmesartan 
plus amlodipine compared with the component monothera-
pies (P , 0.001). Blood pressure reductions were greater 
with olmesartan 20 mg in combination with amlodipine 
5 mg (–22.6/–14.6 mmHg, respectively), compared with 
monotherapy with olmesartan 20 or 40 mg (–12.8/–9.9 
and –15.4/–10.9 mmHg, respectively) and compared with 
amlodipine 5 or 10 mg (–14.3/–10.0 and –18.9/–13.3 mmHg, 
respectively). These results provide a practical demonstration 
of the principle that combination therapy is superior to mono-
therapy, and that combining two agents at a lower dose pro-
duces larger blood pressure reductions than titrating the dose 
of monotherapy. The proportion of patients achieving their 
blood pressure goal (,140/90 mmHg, or ,130/80 mmHg for 
patients with diabetes) showed a similar pattern of response, 
with all doses of combination therapy showing higher rates 
of goal achievement compared with the same dose of each 
monotherapy. The combination was well tolerated, and as 
highlighted earlier, showed particular benefits in terms of 
reducing the occurrence of peripheral edema, an adverse 
event frequently associated with amlodipine 10 mg. In this 
study, combining amlodipine 10 mg with olmesartan (10 mg, 
20 mg, or 40 mg) reduced the frequency of edema seen 
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with the higher dose of this CCB, with a statistically signifi-
cant reduction observed for olmesartan 20 mg/amlodipine 
10 mg (P = 0.032) and olmesartan 40 mg/amlodipine 10 mg 
(P = 0.011). A further illustration of the benefits of combina-
tion therapy comes from a randomized study of the effects of 
adding olmesartan (10–40 mg) in 755 patients with moderate-
to-severe hypertension who had not shown an adequate 
response to 8 weeks of treatment with amlodipine 5 mg.52 
Significant reductions in blood pressure were observed 
after 8 weeks of double-blind treatment with all doses of 
olmesartan and amlodipine combination therapy compared 
with patients randomized to continue receiving amlodipine 
5 mg (P , 0.03). The benefits of combination therapy were 
also seen in the significantly higher level of blood pressure 
goal achievement with olmesartan 40 mg/amlodipine 5 mg 
(51%) and olmesartan 20 mg/amlodipine 5 mg (54%) com-
pared with the group that continued on amlodipine 5 mg 
(30%; P , 0.0001). In each of these   studies, olmesartan in 
combination with amlodipine was well tolerated.
In regard to the combination of olmesartan with HCTZ, 
greater reductions in seated diastolic blood pressure and 
systolic blood pressure were observed with olmesartan 
(10 mg, 20 mg, or 40 mg) plus HCTZ (12.5 or 25 mg) 
than monotherapy with either component at 8 weeks in 
a randomized, double-blind, factorial design study in 
502 patients with grade 2 hypertension.48 Blood pressure 
reductions with olmesartan 20 mg plus HCTZ 12.5 mg were 
greater than monotherapy of either olmesartan 20 mg or 
HCTZ 12.5 mg. Moreover, blood pressure reductions in the 
group that received the 20/12.5 mg combination were larger 
than the blood pressure reductions seen in the groups that 
received monotherapy at higher doses (olmesartan 40 mg and 
HCTZ 25 mg, respectively), again highlighting the benefits 
of combination therapy over titration of monotherapy. In a 
secondary analysis of this study, the proportion of patients 
achieving their blood pressure goals was also found to be 
greater in those receiving combination therapy compared 
with monotherapy.49 A recent addon study in patients 
with moderate-to-severe hypertension (n = 972) who had 
inadequate blood pressure control with olmesartan 40 mg 
provides further support for the efficacy of combination 
therapy. Compared with patients randomized to continue 
with olmesartan 40 mg alone, those randomized to receive 
HCTZ (12.5 mg and 25 mg) showed significant dose-related 
reductions in clinic systolic blood pressure and diastolic 
blood pressure (P , 0.0001), as well as significant reductions 
in a  mbulatory systolic blood pressure and diastolic blood 
pressure and improvements in goal rate achievement.53 
The benefits of combination therapy with the inclusion 
of dose titration are illustrated by a treat-to-target study 
that used a stepwise treatment intensification algorithm. 
The efficacy of a 12-week olmesartan-based regimen was 
investigated in 276 patients with grade 1 and 2 hypertension 
in a randomized, double-blind, placebo-controlled, titration 
study.51 Patients received olmesartan 20 mg for 3 weeks 
after which those who did not achieve an adequate level of 
blood   pressure control were uptitrated to 40 mg for 3 weeks, 
and then in the two following 3-week periods, HCTZ 
12.5 mg was added and uptitrated to 25 mg. Blood pressure 
reductions occurred in a progressive treatment-related and 
dose-related manner. The reductions in seated diastolic 
blood pressure and systolic blood pressure increased at each 
dose titration step, with the greatest reductions observed 
in patients who received olmesartan 40 mg plus HCTZ 
25 mg. These   studies have also shown that the olmesartan/
HCTZ combination is well tolerated, with adverse events of 
mild-to-moderate severity.48,51,53
These studies highlight the benefits of combining two 
antihypertensive agents from different classes, but there are 
some patients, estimated to represent around 15%–20% of the 
patient population, who cannot be controlled with two drugs, 
and who require a combination of three or more antihyper-
tensive agents. For such patients, the 2009 reappraisal of the 
European guidelines suggests that a combination containing a 
renin-angiotensin system blocker, CCB, and thiazide diuretic 
is rational.7 Recent clinical studies bear this out and have 
shown that triple therapy with an ARB, CCB, and a diuretic 
significantly reduces blood pressure compared with dual com-
bination therapy.54,55
The clinical benefit (seated diastolic blood pressure 
reduction $2 mmHg) of triple combination therapy with 
olmesartan 40 mg, amlodipine 10 mg, and HCTZ 25 mg has 
been compared with that of dual combination therapy with 
the individual components in TRINITY (the TRIple therapy 
with olmesartan medoxomil, amlodipine, and hydrochlo-
rothiazide in hyperteNsIve patienTs studY), conducted in 
2492 patients with moderate-to-severe hypertension.54 After 
12 weeks, seated diastolic blood pressure and systolic blood 
pressure reductions were significantly greater with triple 
combination therapy compared with dual combinations 
(P , 0.001), ie, least squares mean reductions in seated dia-
stolic blood pressure of –21.8 versus –15.1 to –18.0 mmHg; 
least squares mean reductions in seated systolic blood 
pressure of –37.1 versus –27.5 to –30.0 mmHg. Also, a 
significantly greater proportion of patients using triple 
therapy reached target blood pressures (P , 0.001 versus 
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dual combinations). Significantly greater reductions in mean 
24-hour blood pressure were also observed for the triple com-
bination compared with dual therapy (P , 0.0001), showing 
that duration of action is increased as well as magnitude 
of effect.56 Triple combination therapy was well tolerated, 
with the majority of adverse events being mild-or-moderate 
in severity. There was no difference in the incidence of 
treatment-emergent adverse events between triple and dual 
combination therapies.
A further insight into the potential of combination therapy 
comes from the BP-CRUSH (Blood Pressure ContRol in all 
sUbgroupS with Hypertension) study which used a stepwise, 
treat-to-target based approach.57 The study involved 999 
patients uncontrolled on monotherapy who received olmesar-
tan plus amlodipine 20/5 mg for 4 weeks after which those 
who did not meet a specified blood pressure target had their 
treatment intensified after intervals of 4 weeks by titration to 
40/5 mg, and then 40/10 mg by the addition of HCTZ 12.5 mg 
and finally by titration of this to 25 mg. At the end of the dual 
combination phase after 12 weeks, the cumulative percent-
age of patients who had achieved the primary end point of 
seated systolic blood pressure ,140 mmHg (,130 mmHg 
in diabetics) was 75.8%, and at the end of the triple combi-
nation phase after 20 weeks, the cumulative percentage who 
had achieved this end point was 90.3%.57
It should also be pointed out that a triple combination 
based upon the ARB valsartan has also become available and 
shown promising efficacy in clinical studies. In one study, 
408 patients with grade 2 hypertension were randomized to 8 
weeks of treatment with valsartan plus amlodipine 160/10 mg 
or amlodipine 10 mg. After 4 weeks, HCTZ 12.5 mg was 
added if mean systolic blood pressure was .130 mmHg. 
By the end of the 8-week study, patients who had received 
valsartan plus amlodipine plus HCTZ showed significantly 
greater mean seated blood pressure reductions from baseline 
(30.5/13.8 mmHg) than those who received amlodipine plus 
HCTZ (24.3/8.3 mmHg, P , 0.0001). Significant reductions 
in ambulatory blood pressure were also seen in a subanaly-
sis of 283 subjects from a separate study of patients with 
moderate-to-severe hypertension who had received 6 weeks 
of randomized treatment with valsartan plus amlodipine plus 
HCTZ 320/10/25 mg or each component dual   combination. 
In the first phase of this study, each group received a lower-
dose dual combination and HCTZ was added to one group 
after a week with all doses being titrated before the final 
6 weeks. At the end of the study, the mean reduction from 
baseline in 24-hour mean ambulatory systolic blood pres-
sure/diastolic blood pressure was 30.3/19.7 mmHg with 
amlodipine plus valsartan plus hydrochlorothiazide, and 
18.8–24.1/11.7–15.5 mmHg with the dual combinations 
(P , 0.01 for each triple versus dual comparison).58
A further recent development is the availability of dual 
and triple combinations based on the direct renin inhibitor, 
aliskiren. This was demonstrated by a study of 412 patients 
with grade 2 hypertension who were randomized to 8 weeks 
of treatment with aliskiren plus amlodipine (150/5 mg) or 
amlodipine (5 mg), force titrated to aliskiren plus amlodipine 
plus HCTZ (300/10/25 mg) or aliskiren plus amlodipine 
(300/10 mg). Both treatments reduced mean seated blood 
pressure, but the reductions seen with the triple combination 
were larger and enabled 72.6% of patients to achieve blood 
pressure goal, compared with 53.2% of dual combination 
recipients.59
Further analyses of these studies and new studies with 
triple combination therapy should help to make clear the 
patient populations in which triple combinations are most 
suitable. Here it may be informative to look at the long-term 
extension phase of the COACH study during which HCTZ 
could be added to olmesartan plus amlodipine, with all three 
agents titrated according to the investigators’ discretion. Not 
surprisingly, it could be seen at the end of the study that 
the patients who had required HCTZ had the higher blood 
pressure levels at baseline than patients who had reached 
the end of the study on the olmesartan plus amlodipine dual 
combination.60 Thus, some of the patients who will likely 
benefit from the use of the triple combination will be those 
with more severe forms of hypertension.
Fixed-dose combination therapy
A further important issue related to the use of combination 
therapy is that represented by the choice of single-pill fixed-
dose combinations. In those patients who require two or 
more drugs to control blood pressure, the use of fixed-dose 
combination of two drugs is recommended in   European 
guidelines.6,7 In this regard, the major role played by compli-
ance with therapy for effective management of high blood 
pressure is widely recognized. Indeed, poor compliance 
is common in the treatment of chronic diseases such as 
hypertension, with an estimated 30%–50% of patients not 
complying with antihypertensive therapy.61 As the number 
of daily administrations increases, compliance with treat-
ment decreases and, thus, the lack of compliance represents 
a common and major problem in the clinical management 
of hypertension. Therefore, the use of fixed-dose combina-
tion therapy can help to simplify treatment regimens and to 
ensure higher compliance with therapy.62
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A meta-analysis of nine studies using fixed-dose combina-
tion therapies, including four in hypertensive patients, found 
a 26% decrease in risk of noncompliance compared with a 
free-drug component regimen.63 The risk of noncompliance 
decreased by 24% with fixed-dose combination therapy in the 
four studies of hypertensive patients (P , 0.0001). The use of 
fixed-dose combination therapy may also be associated with 
improved blood pressure control. A meta-analysis of three stud-
ies with fixed-dose combinations of antihypertensive drugs, 
which reported normalization of blood pressure, has shown a 
trend towards greater blood pressure control, compared with 
the corresponding free drug combination (Figure 2).17
Various dual combinations of ARBs with HCTZ or amlo-
dipine are available as fixed-dose combinations. Recently 
two fixed-dose combinations of three agents including an 
ARB have become available, ie, valsartan with amlodipine 
and HCTZ, and olmesartan with amlodipine and HCTZ. The 
development of ARB-based triple fixed-dose combinations 
like these may be helpful to improve blood pressure control 
and compliance in clinical practice.
Conclusion
Hypertension is a growing public health concern, and the use 
of combination therapy can aid treatment optimization and 
improve blood pressure control. ARB-based dual and triple 
combinations, such as those based upon olmesartan, provide 
greater reductions in blood pressure than the component 
monotherapies and dual therapies, respectively, are well 
tolerated, and can also help to improve compliance.
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